share_log

MIRA Pharmaceuticals | 8-K: Current report

MIRA Pharmaceuticals | 8-K: Current report

MIRA Pharmaceuticals | 8-K:重大事件
美股SEC公告 ·  09/13 04:34

Moomoo AI 已提取核心訊息

MIRA Pharmaceuticals held its 2024 Annual Meeting on September 12, 2024, with 63.72% of outstanding shares represented. Stockholders elected five directors: Erez Aminov, Michael Jerman, Matthew Del Giudice, M.D., Denil Nanji Shekhat, M.D., and Edward MacPherson, to serve until the next Annual Meeting.The appointment of Cherry Bekaert LLP as the independent registered public accounting firm for FY2024 was ratified. Shareholders also approved amendments to the 2022 Omnibus Incentive Plan to increase available shares. The proposal to adjourn the meeting if necessary was withdrawn as other proposals passed.Voting results showed strong support for all proposals, with director nominees receiving over 6.6 million votes each, and the accounting firm appointment garnering over 9.4 million votes in favor.
MIRA Pharmaceuticals held its 2024 Annual Meeting on September 12, 2024, with 63.72% of outstanding shares represented. Stockholders elected five directors: Erez Aminov, Michael Jerman, Matthew Del Giudice, M.D., Denil Nanji Shekhat, M.D., and Edward MacPherson, to serve until the next Annual Meeting.The appointment of Cherry Bekaert LLP as the independent registered public accounting firm for FY2024 was ratified. Shareholders also approved amendments to the 2022 Omnibus Incentive Plan to increase available shares. The proposal to adjourn the meeting if necessary was withdrawn as other proposals passed.Voting results showed strong support for all proposals, with director nominees receiving over 6.6 million votes each, and the accounting firm appointment garnering over 9.4 million votes in favor.
MIRA製藥公司於2024年9月12日召開2024年年度會議,出席的流通股份比例爲63.72%。股東選舉了五位董事:Erez Aminov、Michael Jerman、Matthew Del Giudice萬.D.、Denil Nanji Shekhat萬.D.和Edward MacPherson,他們將任職至下次年度會議。Cherry Bekaert LLP被任命爲2024財政年度的獨立註冊公共會計師事務所,此項任命獲得通過。股東還批准了2022年綜合激勵計劃的修正案,以增加可用股份。如果有必要,延長會議的提案被撤回,因爲其他提案已通過。投票結果顯示所有提案都得到了強烈的壓力位支持,董事提名人每人獲得超過660萬票,而會計事務所的任命獲得超過940萬票的支持。
MIRA製藥公司於2024年9月12日召開2024年年度會議,出席的流通股份比例爲63.72%。股東選舉了五位董事:Erez Aminov、Michael Jerman、Matthew Del Giudice萬.D.、Denil Nanji Shekhat萬.D.和Edward MacPherson,他們將任職至下次年度會議。Cherry Bekaert LLP被任命爲2024財政年度的獨立註冊公共會計師事務所,此項任命獲得通過。股東還批准了2022年綜合激勵計劃的修正案,以增加可用股份。如果有必要,延長會議的提案被撤回,因爲其他提案已通過。投票結果顯示所有提案都得到了強烈的壓力位支持,董事提名人每人獲得超過660萬票,而會計事務所的任命獲得超過940萬票的支持。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息